Study guide
11.3 Renal/Hepatic Impairment & Dose Adjustment
APC Intern Written Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals
2 Legal Framework: PBS & Medicine Schedules
2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)
3 Legal Framework: Privacy, National Law & Pharmacy Board
3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards
4 Patient-Centred Medication Management
4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management
5 Primary Care & Judicious Use of Medicines
5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices
6 Dispensing & Clinical Appropriateness
6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes
7 Counselling & Acute Care
7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response
8 Therapeutics: Cardiovascular & Endocrine
8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders
9 Therapeutics: Infection, Respiratory & Gastrointestinal
9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health
10 Therapeutics: Neurology, Psychiatry & Pain
10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics
11 Therapeutics: Special Populations & Systems
11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment
12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology
12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management
13 Monitoring: Clinical Review
13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications
14 Monitoring: Safety & Adverse Drug Reactions
14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring
15 Compounding Medicines
15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations
16 Pharmaceutical Calculations
16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations
17 Promote Health & Well-Being
17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency
11.3 Renal/Hepatic Impairment & Dose Adjustment
Key Takeaways Explain This Topic AI
Use eGFR (and clinical context including age, weight, and acute kidney injury trajectory) to guide renally cleared drug dosing; do not assume ‘normal dose’ without checking AMH.
High-yield renally cleared or accumulation-prone examples include metformin, DOACs, gabapentin/pregabalin, many antibiotics, and allopurinol — thresholds and strategies are product-specific.
Nephrotoxins such as NSAIDs and aminoglycosides require risk awareness, hydration/context checks, and monitoring; combination nephrotoxic load multiplies harm.
Hepatic impairment alters high extraction and hepatically metabolised drugs unpredictably; avoid guessing — use AMH hepatic advice and monitor for accumulation effects.
Choose dose adjust versus avoid based on evidence and residual risk; watch for sedation, bleeding, and hypoglycaemia as common accumulation syndromes.
Last updated: August 2026
11.3 Renal/Hepatic Impairment & Dose Adjustment
Quick Answer: For renal impairment, anchor decisions on current eGFR/clinical kidney status , identify renally cleared or nephrotoxic medicines, then dose-adjust or avoid per AMH — never invent cut-offs. For hepatic impairment, respect unpredictability of metabolism and high-extraction drugs, start from product guidance, and monitor for accumulation (sedation, bleed risk, hypoglycaemia).
Renal and hepatic dosing is a core APC Intern Written skill under Standards 3.2 (implement medication plans safely) and 3.3 (monitor and modify therapy). Restricted open-book rules mean you should look up precise thresholds in AMH during the exam, but you must recognise which medicines need the look-up , what clinical information matters, and which adverse syndromes signal accumulation.
eGFR for dosing — what it is and what it is not
Estimated glomerular filtration rate ( eGFR ) from serum creatinine equations is the usual community and hospital prompt for renal drug dosing. Key caveats:
- eGFR assumes steady state; acute kidney injury (AKI) can make a single number lag behind true function
- Extremes of muscle mass, diet, amputation, and some drugs affecting creatinine secretion distort estimates
For some drugs, product information historically used creatinine clearance (CrCl) approximations (e.g. Cockcroft–Gault concepts) — follow the reference method stated for that medicine
Older adults may have “normal” creatinine with reduced GFR — do not rely on creatinine alone
Practical pharmacist workflow:
- Identify if the medicine is renally cleared, has active renally cleared metabolites, or is nephrotoxic
- Obtain recent renal function and trend (improving vs declining)
- Check AMH/product renal dosing table for adjust / extend interval / avoid
- Consider interacting nephrotoxins and hydration status
Plan monitoring (symptoms, labs, levels if applicable) and communicate with prescriber when doses look mismatched
High-yield renally cleared drugs
Memorise patterns , then verify numbers:
Metformin
Metformin is renally cleared. Accumulation raises lactic acidosis risk in significant renal impairment, AKI, dehydration, or hypoxic states. Community pharmacists should check eGFR at initiation and when function may have changed, counsel sick-day rules (hold during severe gastroenteritis/dehydration per local guidance), and flag iodinated contrast pathways in hospital contexts. Do not continue usual doses blindly after marked eGFR decline.
DOACs (direct oral anticoagulants)
Apixaban, rivaroxaban, dabigatran, and edoxaban have renal clearance components to differing degrees. Renal impairment increases bleeding risk via drug accumulation and patient comorbidity. Dosing may depend on eGFR/CrCl, age, weight, and interacting medicines (P-gp/CYP patterns). Exam skill: recognise that renal function is mandatory in DOAC review; never assume the stroke-prevention dose is automatically correct without kidney data.
Gabapentin and pregabalin
Both are renally cleared. In reduced eGFR they accumulate, causing sedation, dizziness, confusion, myoclonus, and falls — especially in older adults. Dose reduction or extended intervals are standard. Counsel against abrupt self-escalation for pain.
Many antibiotics
Examples of renally adjusted or cautioned agents (class-level):
- Beta-lactams such as amoxicillin, flucloxacillin (context-dependent), cephalexin, ceftriaxone nuances
- Ciprofloxacin and other renally cleared fluoroquinolones
- Aminoglycosides (gentamicin) — renally cleared and nephrotoxic/ototoxic; levels and short courses
- Vancomycin — renal clearance with therapeutic drug monitoring in serious infection
Nitrofurantoin — efficacy and safety concerns when GFR is too low for urinary concentration/safety (check current cut-offs)
Trimethoprim ± sulfamethoxazole — renal dosing and hyperkalaemia risk
Stewardship still applies: adjust dose and ensure indication/duration remain appropriate.
Allopurinol
Allopurinol and its metabolite oxypurinol accumulate in renal impairment. Lower starting doses and careful titration reduce severe cutaneous adverse reaction risk (especially with other risk factors such as HLA-B*5801 in at-risk populations). Do not start high-dose allopurinol in advanced CKD without renal-adjusted thinking.
Other frequent renally adjusted community medicines
Sitagliptin and some other diabetes agents, digoxin, lithium, morphine/oxycodone metabolite considerations, antiviral agents (e.g. aciclovir concepts), and colchicine caution frames — again, AMH first for thresholds.
Nephrotoxins — NSAIDs, aminoglycosides, and combination risk
NSAIDs (ibuprofen, naproxen, diclofenac, COX-2 inhibitors to a variable extent) can reduce afferent arteriolar prostaglandin support of GFR, precipitating AKI — especially with:
- Dehydration or intercurrent illness
- ACE inhibitor/ARB + diuretic combinations (“triple whammy” with NSAID)
- Heart failure or CKD baseline
- Older age
Community counselling: prefer paracetamol when anti-inflammatory effect is not essential; short courses if NSAIDs are used; check other nephrotoxins; escalate if oliguria, oedema, or rising creatinine.
Aminoglycosides cause concentration- and duration-related nephrotoxicity and ototoxicity. Hospital protocols use extended-interval dosing, levels, and renal monitoring. Community pharmacists may see discharge scripts or shared-care — flag duration creep and renal trajectory.
Other nephrotoxin concepts: iodinated contrast, calcineurin inhibitors, high-dose methotrexate with inadequate hydration/alkalisation, and amphotericin (hospital). Combination risk multiplies — always review the full list.
Hepatic impairment — principles without false precision
Unlike eGFR, there is no single liver number that reliably predicts drug clearance for all medicines. Child–Pugh categories appear in some product information, but many labels remain qualitative (“caution,” “avoid in severe impairment”).
Conceptual pharmacology for exams:
High hepatic extraction drugs are sensitive to hepatic blood flow and first-pass metabolism; oral bioavailability may rise when liver function/flow falls, increasing systemic exposure
Low extraction, capacity-limited drugs depend more on hepatocyte metabolic function and protein binding changes
- Hypoalbuminaemia increases unbound fraction of highly protein-bound drugs
- Cholestasis may impair biliary excretion of some agents
- Hepatorenal syndrome links liver failure to kidney failure — dual organ caution
Examples of caution patterns (verify per medicine):
Sedatives and opioids: exaggerated CNS depression; prefer lower doses and longer intervals; avoid stacking agents
Anticoagulants/antiplatelets: higher bleeding risk from both pharmacology and variceal/coagulopathy disease risk
Hepatotoxic drugs (high-dose paracetamol patterns, isoniazid, some antifungals, methotrexate): extra vigilance or avoidance depending on severity
Statins and other metabolised agents: interaction and impairment cautions vary — look up rather than generalise
Hard rule: do not invent percentage dose cuts for hepatic disease without a reference. Say “requires AMH/product review and likely specialist input in severe impairment,” then apply monitoring logic.
Monitor for accumulation syndromes
When doses are too high for organ function, presentations often cluster:
- Syndrome Suggestive clues Example drug links
- CNS depression / falls Sedation, confusion, ataxia Gabapentinoids, opioids, benzodiazepines
- Bleeding Bruising, melaena, anaemia, high INR if warfarin DOACs, warfarin, antiplatelets ± interactions
- Hypoglycaemia Sweating, tremor, confusion, low BGL Sulfonylureas (renal accumulation risk), insulin mismatch
- Lactic acidosis concern Unwell metformin patient with AKI Metformin + renal failure
- Serotonin toxicity / other Drug-specific Always consider interaction + organ failure
Monitoring plans should state what to check (symptoms, eGFR, LFTs, INR, BGL, drug levels) and when to re-review after initiation or acute illness.
Dose adjust versus avoid
Decision framework:
- Is the drug essential? If not, deprescribe or switch to a renally/hepatically cleaner alternative
- Is there an evidence-based adjusted regimen? If yes, implement and document
Is residual risk still high even at adjusted doses? Prefer avoid (e.g. NSAIDs in advanced CKD with prior AKI, nitrofurantoin when GFR too low for benefit/safety, methotrexate in significant renal impairment without specialist protocols)
Is the patient in AKI rather than stable CKD? Many chronic adjusted doses are unsafe in acute decline — hold or temporarily revise
- Communicate: notify prescriber with specific concern (drug + eGFR + proposed action)
- Worked scenario style thinking
eGFR 28 mL/min/1.73 m² and metformin: check whether continuation/dose is still appropriate; review sick-day rules; discuss alternatives for glycaemic control if thresholds breached
Older adult on gabapentin 300 mg three times daily with falling eGFR and new daytime sedation: suspect accumulation; recommend review for renal-adjusted dosing
Patient with cirrhosis and new oxycodone for pain: start low, go slow, avoid multi-sedative stacks, monitor constipation and encephalopathy risk
Triple therapy ACEI + diuretic + OTC ibuprofen for back pain: counsel nephrotoxic combination risk and safer analgesia
Exam discipline with open-book AMH
You will not memorise every cut-off — and you should not. You will be expected to:
- Spot renally cleared and nephrotoxic agents quickly
- Ask for or use eGFR/AKI context
- Choose adjust vs avoid vs monitor
- Recognise accumulation toxidromes
- Avoid hepatic dosing fiction without references
That combination is the intern-level standard for protecting patients with organ impairment.